#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Raynaud's phenomenon Hypersensitivity pneumonitis Lymphangiosarcoma Richter's syndrome Retinal artery occlusion Cold type haemolytic anaemia Dementia with Lewy bodies Amyloidosis Cholangiosarcoma Leiomyosarcoma recurrent Arrhythmogenic right ventricular dysplasia Autoinflammation with infantile enterocolitis Pseudoxanthoma elasticum Peripheral T-cell lymphoma unspecified Propionic acidaemia More trials…

    Learn about Rare Diseases

    Glycogen storage disease type II – Basic Information Wiskott-Aldrich syndrome Synovial sarcoma recurrent – Life with Disease Langerhans’ cell histiocytosis Langerhans cell sarcoma – Life with Disease MELAS syndrome Synovial sarcoma metastatic – Life with Disease Glycogen storage disease type I – Diagnostics Hepatoblastoma Hereditary angioedema – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Mva-Hbvac Benserazide Hydrochloride Fenebrutinib Belzutifan Arginine Nadunolimab Gadobutrol Tafluprost Adezunap Livmoniplimab Tigulixostat Sot102 L-Tyrosine INSULIN DETEMIR Crizotinib Latozinemab Relatlimab IBANDRONIC ACID Nanatinostat 68Ganota-Anti-Her2 Vhh1 More therapies…

    Learn about Your Condition

    Coronary artery occlusion Post-acute COVID-19 syndrome Enteritis Dermatitis Thermal burn Factor IX deficiency Splenic marginal zone lymphoma Oesophagectomy Renal transplant Ovarian cancer metastatic Erosive oesophagitis Amyotrophic lateral sclerosis Systemic candida Cholangiocarcinoma Appendicitis perforated More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Follicular lymphoma

  • Study on Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma Not Eligible for Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Follicular lymphoma
    Investigated Drugs:
    • Rituximab
    Italy

  • Study Comparing Shortened vs Standard Chemotherapy with Rituximab for Initial Treatment of High Tumor Burden Follicular Lymphoma in Newly Diagnosed Patients

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Follicular lymphoma
    Investigated Drugs:
    • Bendamustine
    • Bendamustine Hydrochloride
    • Vincristine
    Italy

  • Study Comparing Axicabtagene Ciloleucel with Standard Treatment for Patients with Relapsed or Refractory Follicular Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Axicabtagene Ciloleucel
    • Bendamustine Hydrochloride
    • Cyclophosphamide
    France Germany Italy Spain

  • Study of capivasertib tablets in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Marginal zone lymphoma
    • Follicular lymphoma
    • Mantle cell lymphoma
    Investigated Drugs:
    • Capivasertib
    Spain

  • Study of Rapcabtagene Autoleucel and Ibrutinib for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Other Blood Cancers

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Primary mediastinal large B-cell lymphoma
    • High-grade B-cell lymphoma
    • Follicular lymphoma
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Fludarabine Phosphate
    • Rapcabtagene Autoleucel
    Austria France Germany Italy Spain

  • Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Ibrutinib
    Czechia France Hungary Italy Poland Spain +1
Previous Page
1 2 3 4 5 6 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!